TGF-β receptor I inhibitor enhances response to enzalutamide in a pre-clinical model of advanced prostate cancer

Cancer statistics, 2018

(2018) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Aberrant TGF-β Signaling Drives Castration-Resistant Prostate Cancer in a Male Mouse Model of Prostate Tumorigenesis

(2017) Hong Pu et al.   ENDOCRINOLOGY

Navigating the evolving therapeutic landscape in advanced prostate cancer

(2017) E. David Crawford et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

TGF-β Tumor Suppression through a Lethal EMT

(2016) Charles J. David et al.   CELL

αvβ6 integrin is required for TGFβ1-mediated matrix metalloproteinase2 expression

(2015) Anindita Dutta et al.   BIOCHEMICAL JOURNAL

A Targetable GATA2-IGF2 Axis Confers Aggressiveness in Lethal Prostate Cancer

(2015) Samuel J. Vidal et al.   CANCER CELL

Multinucleation and Mesenchymal-to-Epithelial Transition Alleviate Resistance to Combined Cabazitaxel and Antiandrogen Therapy in Advanced Prostate Cancer

(2015) S. K. Martin et al.   CANCER RESEARCH

TGF-β Promotes Heterogeneity and Drug Resistance in Squamous Cell Carcinoma

(2015) Naoki Oshimori et al.   CELL

Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer

(2015) Robert J. van Soest et al.   EUROPEAN UROLOGY

Efficacy of Enzalutamide Following Abiraterone Acetate in Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer Patients

(2015) Arun A. Azad et al.   EUROPEAN UROLOGY

Die-hard survivors: heterogeneity in apoptotic thresholds may underlie chemoresistance

(2015) Angela Ogden et al.   Expert Review of Anticancer Therapy

Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study

(2015) Charles J Ryan et al.   LANCET ONCOLOGY

Therapy-induced tumour secretomes promote resistance and tumour progression

(2015) Anna C. Obenauf et al.   NATURE

Prevalence of Prostate Cancer Clinical States and Mortality in the United States: Estimates Using a Dynamic Progression Model

(2015) Howard I. Scher et al.   PLoS One

Treatment sequencing in metastatic castrate-resistant prostate cancer

(2014) Oliver Sartor et al.   ASIAN JOURNAL OF ANDROLOGY

Transforming Growth Factor-  as a Therapeutic Target in Hepatocellular Carcinoma

(2014) G. Giannelli et al.   CANCER RESEARCH

Cofilin Drives Cell-Invasive and Metastatic Responses to TGF-β in Prostate Cancer

(2014) Joanne Collazo et al.   CANCER RESEARCH

Contributions of epithelial-mesenchymal transition and cancer stem cells to the development of castration resistance of prostate cancer

(2014) Ping Li et al.   Molecular Cancer

AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer

(2014) Emmanuel S. Antonarakis et al.   NEW ENGLAND JOURNAL OF MEDICINE

Enzalutamide in Metastatic Prostate Cancer before Chemotherapy

(2014) Tomasz M. Beer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Expression and significance of E-cadherin, N-cadherin, transforming growth factor-β1 and Twist in prostate cancer

(2014) Ge-Liang Liu et al.   Asian Pacific Journal of Tropical Medicine

The Steroid Receptor Coactivator-3 Is Required for the Development of Castration-Resistant Prostate Cancer

(2013) Jean C-Y. Tien et al.   CANCER RESEARCH

Activity of Cabazitaxel in Castration-resistant Prostate Cancer Progressing After Docetaxel and Next-generation Endocrine Agents

(2013) Carmel J. Pezaro et al.   EUROPEAN UROLOGY

Evolutionary functional analysis and molecular regulation of the ZEB transcription factors

(2012) Alexander Gheldof et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study

(2012) Karim Fizazi et al.   LANCET ONCOLOGY

Vav3 Enhances Androgen Receptor Splice Variant Activity and Is Critical for Castration-Resistant Prostate Cancer Growth and Survival

(2012) Stephanie O. Peacock et al.   MOLECULAR ENDOCRINOLOGY

TGFβ signalling in context

(2012) Joan Massagué   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy

(2012) Howard I. Scher et al.   NEW ENGLAND JOURNAL OF MEDICINE

Taxane-Induced Blockade to Nuclear Accumulation of the Androgen Receptor Predicts Clinical Responses in Metastatic Prostate Cancer

(2011) M. S. Darshan et al.   CANCER RESEARCH

Master Transcription Factors Determine Cell-Type-Specific Responses to TGF-β Signaling

(2011) Alan C. Mullen et al.   CELL

Characterising the castration-resistant prostate cancer population: a systematic review

(2011) M. Kirby et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Circulating Tumor Cells from Patients with Advanced Prostate and Breast Cancer Display Both Epithelial and Mesenchymal Markers

(2011) A. J. Armstrong et al.   MOLECULAR CANCER RESEARCH

Tubulin-Targeting Chemotherapy Impairs Androgen Receptor Activity in Prostate Cancer

(2010) M.-L. Zhu et al.   CANCER RESEARCH

N-cadherin increases after androgen deprivation and is associated with metastasis in prostate cancer

(2010) Karin Jennbacken et al.   ENDOCRINE-RELATED CANCER

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

(2010) Johann Sebastian de Bono et al.   LANCET

Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance

(2010) Hiroshi Tanaka et al.   NATURE MEDICINE

Dysfunctional Transforming Growth Factor-  Receptor II Accelerates Prostate Tumorigenesis in the TRAMP Mouse Model

(2009) H. Pu et al.   CANCER RESEARCH

Targeting TGF-β in prostate cancer: therapeutic possibilities during tumor progression

(2009) Elisabeth Jones et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Preferential Utilization of Imp7/8 in Nuclear Import of Smads

(2008) Xiaohao Yao et al.   JOURNAL OF BIOLOGICAL CHEMISTRY